Ginkgo Bioworks Holdings, Inc.
HealthcareNYSE:DNA · New York Stock Exchange
-$0.11 today
Vol 0.70M · Avg 1.26M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-61.5%
avg -73.4%
ROIC
-30.7%
avg -50.0%
ROA
-27.9%
avg -46.9%
Analysis
ROA is currently the strongest return metric at -27.9% versus its period average of -46.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Steven Coen | Chief Financial Officer | $438,692.00 | — | 60 | $50,704.00 | 0.08% |
Reshma Shetty | Co-Founder, President & Director | $255,000.00 | — | 45 | $436,422.00 | 0.67% |
Jason Kelly | Co-Founder, Co-COO, CEO & Director | $255,000.00 | — | 45 | $316,483.00 | 0.48% |
Samantha Sutton | Head of People | — | — | — | — | — |
Jennifer Wipf | Co-Chief Operating Officer | — | — | — | — | — |
Karen Tepichin | General Counsel & Secretary | — | — | — | — | — |
Brian O'sullivan | Head of Commercial | — | — | — | — | — |
Daniel Marshall | Senior Manager of Communications & Ownership | — | — | — | — | — |
Bartholomew Canton | Co-Founder & CTO | — | — | — | $436,422.00 | 0.67% |
Austin Che | Co-Founder & Head of Strategy | — | — | — | — | — |
Thomas Knight Jr. | Founder | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
20
$3.90M
Net Sentiment
$3.90M
Net selling
Most Active
Coen Steven P.
10 transactions
1–10 of 20
Analysis
Insiders reported 0 buys worth $0.00 and 20 sells worth $3.90M over the last 12 months. That adds up to net selling of $3.90M. Coen Steven P. was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +48.6% | +6.6% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +48.6% over three years. Forward estimates point to Revenue at +6.6% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Astria Therapeutics, Inc.
ATXS
$718.13M
Valneva SE
NASDAQ:VALN
$507.78M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Who manages DNA?
Ginkgo Bioworks Holdings, Inc. (DNA) lists 11 active executives. The top listed executive is Steven Coen, Chief Financial Officer.
Are DNA insiders buying or selling?
Recent insider activity shows net selling of $1.63M.
Explore More
Continue the stock analysis
Jump to another research area for this company.